Contact Us Menu

Verana Health’s Qdata Geographic Atrophy Links EHR and Imaging Data to Provide a Holistic View of the Patient Journey

Ophthalmology Qdata Module to Provide Real-World Evidence from GA Patients in American Academy of Ophthalmology’s IRIS® Registry

Verana Health Media Contact:
Megan Moriarty
Amendola Communications


SAN FRANCISCO, April 19, 2023 — Verana Health®—a digital health company elevating quality in real-world data (RWD)— will announce the development of Qdata® Geographic Atrophy at ARVO 2023, the annual conference of the Association for Research in Vision and Ophthalmology, which takes place in New Orleans between April 23 to 27. This new offering already provides a comprehensive clinical view of real-world data from almost 350,000 de-identified geographic atrophy (GA) patients, making Verana Health the leading company able to identify GA diagnosis from both electronic health records (EHR) and images for research. As Verana Health ingests even more ophthalmic images in 2023, this number will continue to grow.

Verana Health has developed novel machine learning (ML) and computer vision (CV) algorithms to identify and filter clinical images into high-quality, research-ready image data that provide quality insights. Combining this image data with EHR data from the American Academy of Ophthalmology (Academy) IRIS® Registry (Intelligent Research in Sight) will support researchers in gaining a comprehensive view into the GA patient journey. Verana Health is the Academy’s exclusive end-to-end data curation and analytics partner for the IRIS Registry.

A condition in which large sections of the retina cease to function, GA impacts an estimated 1 million Americans and can cause irreversible vision loss and even blindness. This disease accounts for approximately 20% of legal blindness in the U.S. Approximately 1% of Americans have the atrophic form in at least one eye, but this increases to 3.5% in patients older than 75 and to nearly 25% of people over age 90. 

Qdata Geographic Atrophy includes de-identified data from more than 8,000 providers and 2,600 GA patients who have linked images and is rapidly growing. The module will help researchers evaluate GA disease severity and track disease progression over time using Verana Health’s curation of key variables from ophthalmic images and unstructured notes. These variables include: 

The new module will help life sciences companies in the following ways:

“When it comes to geographic atrophy, a picture truly is worth a thousand words in capturing the size and progression of a lesion and understanding whether there might be concurrent comorbidities such as choroidal neovascularization that could further impact vision,” said Durga Borkar, MD, MMCi, a vitreoretinal surgeon at Duke University Eye Center and a medical advisor to Verana Health. “These are real-world images that are being taken in physicians’ offices outside of a research setting. When you create machine learning algorithms using these images, they’re more broadly applicable than what you might develop using clinical trial images alone.”

The IRIS Registry is one of the largest specialty society clinical data registries in medicine, containing ophthalmic records from more than 78 million patients over approximately 10 years. Verana Health is responsible for IRIS Registry data curation, EHR integration, analytics, practice support, and quality reporting for physicians contributing to the registry. 

“Ophthalmic images historically have been underutilized as a source of real-world data,” said Sujay Jadhav, CEO of Verana Health. “The addition of images to the IRIS Registry EHR data will enable new data-driven insights to support innovations in ophthalmology to ultimately help improve eye care and quality of life for patients with GA and other ophthalmological conditions.”

Research to be presented at ARVO 23

In addition to announcing Qdata Geographic Atrophy with Images at ARVO 2023, Verana Health will present four abstracts:

1. Geographic Atrophy Diagnosis in the IRIS Registry: A Comparison Between Images and ICD-10 Codes

2. Automated Identification of Geographic Atrophy Eyes With and Without Subfoveal Involvement Using Machine Learning and Real-world Ophthalmic Images in the IRIS Registry 

3. Early Treatment Patterns and Outcomes in Patients with Neovascular Age-Related Macular Degeneration Initiating Faricimab: An IRIS Registry Analysis (FARETINA-AMD study) 

4. Early Treatment Patterns and Outcomes in Patients with Diabetic Macular Edema Treated with Faricimab: An IRIS Registry Analysis (FARETINA-DME study)

About Verana Health

Verana Health® is a digital health company elevating quality in real-world data. Verana Health operates an exclusive real-world data network of more than 20,000 healthcare providers (HCPs) and about 90 million de-identified patients, stemming from its strategic data partnerships with the American Academy of Ophthalmology®, American Academy of Neurology, and American Urological Association. Using its clinician-informed and artificial intelligence-enhanced VeraQ® population health data engine, Verana Health transforms structured and unstructured healthcare data into curated, disease-specific data modules, Qdata®. Verana Health’s Qdata helps power analytics solutions and software-as-a-service products for real-world evidence generation, clinical trials enablement, HCP quality reporting, and medical registry data management. Verana Health’s quality data and insights help drive progress in medicine to enhance the quality of care and quality of life for patients. For more information, visit